XFOR

0.06% 0.0004

Handel nachbörslich: .71 0.0068 +0.97%

X 4 Pharmaceuticals Inc (XFOR)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

X 4 Pharmaceuticals Inc

857-529-8300

61 NORTH BEACON STREET, BOSTON, MA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

XFOR's Discussions on Twitter

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-08-30	Fortgesetzt	B. Riley Securities	Buy
2022-12-22	Eingeleitet	Cantor Fitzgerald	Overweight
2022-12-12	Eingeleitet	Piper Sandler	Overweight
2019-12-23	Eingeleitet	Oppenheimer	Outperform
2019-12-18	Eingeleitet	ROTH Capital	Buy
2019-12-09	Hochstufung	Citigroup	Neutral → Buy
2019-12-05	Eingeleitet	B. Riley FBR	Buy
2019-06-07	Eingeleitet	Stifel	Buy
2019-06-05	Eingeleitet	Cowen	Outperform

Alle ansehen

X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten

Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)

X 4 Pharmaceuticals Inc (XFOR)

X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile

X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades

X 4 Pharmaceuticals Inc Aktie (XFOR) Neueste Nachrichten

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market 2024 To Reach $2.33 Billion By 2028 At Rate Of - EIN News

X4 Pharmaceuticals Inc Inc. (XFOR) Price Performance: A Fundamental Analysis Perspective - The InvestChronicle

Top investors say X4 Pharmaceuticals Inc (XFOR) ticks everything they need - SETE News

Unitedhealth Group Inc [UNH] Stock sold by Insider ROOS THOMAS E for $1.62 million - Knox Daily

Should investors be concerned about X4 Pharmaceuticals Inc (XFOR)? - US Post News

Market Watch: X4 Pharmaceuticals Inc (XFOR)’s Noteworthy Gain, Closing at 0.71 - The Dwinnex

Biopharma Layoff Tracker 2024: Oncternal, Biosense Webster, Charles River Laboratories and More Cut Staff - BioSpace

United States Intravenous Iron Drug Market By Application - Third Eye News

North America Medulloblastoma Drug Market By Application – news - Vaccine Storage & Packaging ...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares Acquired by TD Asset Management Inc - Defense World

North America Drug Discovery Outsourcing Market Size USD 3.4 Bn in 2023| CAGR of 7.2%| USD 5.93 Bn by 2032 - Third Eye News

FDA advisers unconvinced by Intercept's liver disease drug benefits, safety - Reuters

Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with - The Bakersfield Californian

Alkem joins $3 bn race for JB Chem as Torrent pauses talks - The Economic Times

North America Addictions Therapeutics Market By Application - Third Eye News

United States 1,3-Dioxane-4-Aceticacid, 6-(Cyanomethyl)-2,2-Dimethyl-, 1,1-Dimethylethyl Ester, (4R,6R) Market Size, Share, Growth & Forecast – Third Eye News - Third Eye News

You might want to take a look at X4 Pharmaceuticals Inc (XFOR) now - SETE News

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA - Chronicle-Tribune

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

X4 Pharmaceuticals Inc (XFOR) stock on the rise: An overview - US Post News

BMRN: Undervalued Biotech Stocks Ready for a Breakout - StockNews.com

Pharmaceutical Intermediates Market Size To Reach USD 14.0 - GlobeNewswire

Ratios Revealed: Decoding X4 Pharmaceuticals Inc (XFOR)’s Financial Health - The Dwinnex

Quoin Pharmaceuticals Announces Insider Share Purchases by Co-Founders CEO and COO - StockTitan

Anosmia Market Innovations Investigated by Size, Share, Industry Analysis, Segments And Forecast To 2033 - WhaTech

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules - StockTitan

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market 2024 - openPR

X4 Pharmaceuticals (NASDAQ:XFOR) Shares Down 1.3% - MarketBeat

The time has not yet come to remove your chips from the table: X4 Pharmaceuticals Inc (XFOR) - SETE News

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs - Quantisnow

EVP Research Swayze Eric acquired $425 worth of shares (11 units at $38.64), increasing direct ownership by 0.03% to 34,907 units (SEC Form 4) - Quantisnow

Amendment: EVP, Finance & CFO Hougen Elizabeth L sold $107,105 worth of shares (2,162 units at $49.54), decreasing direct ownership by 2% to 92,868 units (SEC Form 4) - Quantisnow

Potential Price Increase for Opendoor Technologies Inc (OPEN) After Recent Insider Activity - Knox Daily

Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Filing of Registration Statement on Form F-4 Related to Proposed Merger - StockTitan

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

EVP, Chief Development Officer Geary Richard S sold $32,159 worth of shares (651 units at $49.40), decreasing direct ownership by 0.76% to 84,823 units (SEC Form 4) - Quantisnow

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance

Trading Day Review: X4 Pharmaceuticals Inc (XFOR) Gains Momentum, Closing at 0.70 - The Dwinnex

X4 Pharmaceuticals Inc (XFOR)’s stock rises to 0.70 per share - US Post News

Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech

Alpha Methyldopa Market Advancements Highlighted by Size, Share, Growth, Trends and Industry Forecast (2024... - WhaTech

mRNA Cancer Vaccines And Therapeutics Global Market In The New Analysis By Leading Research Firm - WhaTech

Top 10 pharma companies in India by market cap - Forbes India

North America Drug for Organ Rejection Prophylaxis Market By Application : A Global Perspective on Regional Markets - அக்னி செய்திகள்

Coccidioidomycosis Drug Market Size, Market Resilience in Times of Disruption (2024-2034) - Cineglit

Coccidioidomycosis Drug Market Size, Market Resilience in Times of Disruption (2024-2034) - அக்னி செய்திகள்

Finanzdaten der X 4 Pharmaceuticals Inc-Aktie (XFOR)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie XFOR